Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U. in the first full week after its launch in an ...

A late-stage trial of CT-388 is expected to start this quarter.

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.

Here & Now’s Peter O’Dowd spoke with Sarah Zhang, a reporter for The Atlantic, about how people are searching the web and using the app Telegram to buy next-generation GLP-3 drugs not yet approved by ...

A larger percentage of GLP-1 users say social media and online research are their most trusted source for microdosing ...

The source of this renewed optimism lies in concrete figures related to the U.S. launch of the oral Wegovy variant in January 2026. Market observers believe the daily pill could be a decisive factor ...

Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial ...

Swiss pharmaceutical manufacturer Roche reports phase 2 results for CT-388, pointing to possible expansion in the fast-growing weight-loss market ...

Earlier in January 2026, Viking Therapeutics reported that its obesity drug candidate VK2735 achieved 14.7% weight loss from baseline over 13 weeks in a Phase 2 trial, meeting primary and secondary ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...